Regenxbio Analyst Ratings
Regenxbio Analyst Ratings
Regenxbio Analyst Ratings
Analysts Offer Insights on Healthcare Companies: OptimizeRx (OPRX), PepGen Inc. (PEPG) and RegenXBio (RGNX)
Buy Rating Affirmed for RegenXBio Amid Promising Drug Developments and Solid Financials
UBS Adjusts Price Target on REGENXBIO to $39 From $43, Maintains Buy Rating
RBC Capital Sticks to Its Buy Rating for RegenXBio (RGNX)
RegenXBio (RGNX) Receives a Buy From Barclays
Regenxbio Analyst Ratings
Analysts Offer Insights on Healthcare Companies: QuidelOrtho (QDEL), OrthoPediatrics (KIDS) and RegenXBio (RGNX)
Regenxbio Analyst Ratings
Regenxbio Analyst Ratings
RBC Upgrades REGENXBIO to Outperform From Sector Perform, Lifts Price Target to $35 From $20, 'Impressed by Recent Execution,' Keeps Speculative Risk
Regenxbio Analyst Ratings
Analysts Are Bullish on These Healthcare Stocks: RegenXBio (RGNX), Biomea Fusion (BMEA)
Regenxbio Analyst Ratings
RegenXBio's RGX-202 Hold Rating: Balancing Promising DMD Trial Outcomes With Competitive Market Challenges
Optimistic Outlook for RegenXBio's Gene Therapy Pipeline and Regulatory Prospects Spurs Buy Rating
Analysts Offer Insights on Healthcare Companies: Universal Health (UHS), UniQure (QURE) and RegenXBio (RGNX)
Regenxbio Analyst Ratings